Biopharma M&A In An Era Of Elusive Growth, Capital Triage, and New Competitors
Investor-friendly capital allocation and the rising strength of large biotechs and specialty pharmas have jeopardized Big Pharma’s position of strength in M&A. Analysis by Ernst & Young suggests that industry’s largest companies face unusual challenges – and must adapt to new marketplace realities.
You may also be interested in...
Maybe no company is safe from activists, but there are protective measures that managers and boards can take. What biopharmas can learn from Valeant Pharmaceuticals and Pershing Square’s pursuit of Allergan.
An analysis of alliance deals in 2013 shows pharmas’ continued reliance on heavily structured deals, a strategy that has often frustrated biotechs looking to partner. But the appetite for new IPO listings may be giving them more options, provoking competitive deal terms from licensors.
Big launches, clinical success in key therapeutic areas like cancer immunotherapy, and renewed interest in biotech from a broad investor base floated the biopharma world through 2013’s average year for FDA approvals, the rocky rollout of the Affordable Care Act, and increasing concern about drug prices.